Table 1.
Characteristics of Patients on All-Oral Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection
| Variable | All-Oral Therapy (N=86) |
|---|---|
| Age, yrs | 61.6 ± 5.8 |
| Sex | |
| Male | 81 (94.2%) |
| Female | 5 (5.8%) |
| Race | |
| White | 47 (54.7%) |
| Black | 35 (40.7%) |
| Body Mass Index | |
| <25 | 17 (19.8%) |
| 25-29.9 | 40 (46.5%) |
| ≥30 | 29 (33.7%) |
| Genotype | |
| 1a | 56 (65.1%) |
| 1b | 29 (33.7%) |
| 1a/1b | 1 (1.2%) |
| Viral Load | |
| <800,000 | 3 (3.5%) |
| ≥800,000 | 83 (96.5%) |
| Prior Treatment History | |
| Treatment-naive | 42 (48.8%) |
| Treatment-experienced (PI) | 3 (3.5%) |
| Treatment-experienced (PEG) | 41 (47.7%) |
| Fibrosis Stage | |
| F1 | 1 (1.2%) |
| F2 | 7 (8.1%) |
| F3 | 12 (14.0%) |
| F4 | 59 (68.6%) |
| Not assessed | 7 (8.1%) |
| Cirrhosis | |
| No | 27 (31.4%) |
| Yes | 59 (68.6%) |
| Special Populations | |
| Hepatocellular carcinoma | 4 (4.7%) |
| Hepatitis B virus | 1 (1.2%) |
| HIV | 7 (8.1%) |
| Liver transplant | 7 (8.1%) |
| Treatment Regimen | |
| SOF-SIM-RBV | 26 (30.2%) |
| SOF-SIM | 60 (69.8%) |
PEG, pegylated interferon; PI, protease inhibitor; SOF-SIM, sofosbuvir and simeprevir; SOF-SIM-RBV, sofosbuvir, simeprevir, and ribavirin.